Home / Companies / Marker Therapeutics, Inc. / 1 May 2026
Marker Therapeutics, Inc.: meeting of 1 May 2026
Votes reported on Form N-PX, item by item
40 Form N-PX filers reported votes at the Marker Therapeutics, Inc. meeting of 1 May 2026. Their records fall into 1 item below, in ballot order: management items first, then proposals from security holders. Each bar shows how the reporting filers split; it is not the result of the meeting.
foragainstabstain, withhold or otheramber tick: the portion cast against management
Items
SECTION 14A SAY-ON-PAY VOTESIssuer
Advisory vote on executive pay (say-on-pay)
54 vote records from 40 filers. 0 of the 36 filers that marked the item either way voted against management. 4 filers reported this item without a management mark.
How the largest families voted
| Family | 1. Say-on-pay |
|---|---|
| Vanguard | For |
| Fidelity | For |
| State Street and SPDR | For |
| Northern Trust and FlexShares | For |
| BNY Mellon | For |
* against management. A family's position is the way most of its reported shares were voted across its filers; "split" means no single position led. "No report" means none of the family's filers listed the item.
Questions
How did large funds vote at the Marker Therapeutics, Inc. meeting?
40 Form N-PX filers reported votes at the meeting of 1 May 2026. On say-on-pay, 0 of 36 voted against management (0.0%). The family table lists each of the largest families item by item.
Is this the meeting result?
No. These are the votes of funds and managers that file Form N-PX, counted by filer and by the shares they reported. The certified result, which includes every shareholder, is reported by Marker Therapeutics, Inc. on Form 8-K.
Why are director elections shown as counts only?
Director records name the nominee. This site does not publish pages or rows about individuals, so for director elections it keeps the number of nominees and the split of votes and discards the wording.
Every meeting on file for Marker Therapeutics, Inc.
Provenance: SEC EDGAR, Form N-PX and N-PX/A filings listing Marker Therapeutics, Inc. with a meeting date within three days of 1 May 2026. Proposal titles are the most common wording among filers and are replaced by the SEC category where a wording could name a person. Not verified by the SEC. Filings read through 23 Sep 2026.